October 2025

These snippets from recent studies cover new therapies in T2DM and obesity, in-hospital management, association between meal timing and metabolic health; and insulin treatment.

August 2025

Efficacy and safety of iGlarLixi versus IDegAsp in people with Type 2 diabetes inadequately controlled with basal insulin: a systematic literature review and network meta-analysis of non-Asian studies

July 2025

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL.

July 2025

The ADA 2025 Congress featured significant developments in diabetes management, with Simon Heller chairing an important session on measuring hypoglycemia burden and severity in diabetes patients.

April 2025

Medical-on-the-Go is happy to share highlights from the recently concluded ATTD Congress 2025 Last March 19-22, 2025 in Amsterdam & online.

September 2024

We would like to update you on a recently published randomized, head-to-head, open label phase 3 trial in Chinese people with Type 2 Diabetes Mellitus suboptimally controlled on OADs entitled the Soli-D study.

June 2024

This real-world observational study by Malik et al. shows that initiation of iGlarLixi in people with T2D suboptimally controlled on OADs ± BI or GLP-1 RAs improves glycemic control with a low incidence of hypoglycaemia.

May 2025

Our global expert highlights that individuals living with Type 2 diabetes (T2D) and renal impairment are a key high-risk population and additional considerations need to be made in the management of diabetes.

April 2025

In this episode, we delve into the Efficacy and safety of iGlarLixi versus IDegAsp in Chinese adults with type 2 diabetes, based on the findings from the Soli-D randomized controlled trial.

February 2025

In this episode, Dr Jeremy Pettus and Dr Steve Edelman discuss the increasing role of continuous glucose monitoring (CGM) and time-in-range (TIR) in diabetes management.